BR112015008759A2 - método para a profilaxia e/ou tratamento de sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, agente profilático e/ou terapêutico para sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, uso de um composto, composto, e, composição farmacêutica - Google Patents

método para a profilaxia e/ou tratamento de sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, agente profilático e/ou terapêutico para sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, uso de um composto, composto, e, composição farmacêutica

Info

Publication number
BR112015008759A2
BR112015008759A2 BR112015008759A BR112015008759A BR112015008759A2 BR 112015008759 A2 BR112015008759 A2 BR 112015008759A2 BR 112015008759 A BR112015008759 A BR 112015008759A BR 112015008759 A BR112015008759 A BR 112015008759A BR 112015008759 A2 BR112015008759 A2 BR 112015008759A2
Authority
BR
Brazil
Prior art keywords
symptoms associated
behavioral
neurodegenerative disease
compound
mental illness
Prior art date
Application number
BR112015008759A
Other languages
English (en)
Inventor
Ishikawa Dai
Maeda Kenji
Nakamura Mai
Sato Shinji
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112015008759A2 publication Critical patent/BR112015008759A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

1 / 1 resumo “mã‰todo para a profilaxia e/ou tratamento de sintomas comportamentais e psicolã“gicos associados com doenã‡a neurodegenerativa ou sintomas impulsivos associados com doenã‡a mental, agente profilãtico e/ou terapãšutico para sintomas comportamentais e psicolã“gicos associados com doenã‡a neurodegenerativa ou sintomas impulsivos associados com doenã‡a mental, uso de um composto, composto, e, composiã‡ãƒo farmacãšutica” a presente invenã§ã£o refere-se a um agente profilã¡tico e/ou terapãªutico para sintomas comportamentais e psicolã³gicos associados com doenã§a neurodegenerativa ou sintomas impulsivos associados com doenã§a mental, que contã©m 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butã³xi]-1h- quinolin-2-ona ou um sal deste como um ingrediente ativo.
BR112015008759A 2012-10-25 2013-10-24 método para a profilaxia e/ou tratamento de sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, agente profilático e/ou terapêutico para sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, uso de um composto, composto, e, composição farmacêutica BR112015008759A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718305P 2012-10-25 2012-10-25
US201361782467P 2013-03-14 2013-03-14
PCT/JP2013/079480 WO2014065437A1 (en) 2012-10-25 2013-10-24 Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof

Publications (1)

Publication Number Publication Date
BR112015008759A2 true BR112015008759A2 (pt) 2017-07-04

Family

ID=49585556

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008759A BR112015008759A2 (pt) 2012-10-25 2013-10-24 método para a profilaxia e/ou tratamento de sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, agente profilático e/ou terapêutico para sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, uso de um composto, composto, e, composição farmacêutica

Country Status (22)

Country Link
US (4) US20150272946A1 (pt)
EP (2) EP3848033A1 (pt)
JP (5) JP6329140B2 (pt)
KR (1) KR102245016B1 (pt)
CN (4) CN104755082A (pt)
AR (1) AR093247A1 (pt)
AU (1) AU2013335613B2 (pt)
BR (1) BR112015008759A2 (pt)
CA (1) CA2889196C (pt)
EA (1) EA201590808A1 (pt)
HK (1) HK1212609A1 (pt)
IL (1) IL238402B (pt)
JO (2) JOP20210047A1 (pt)
MX (1) MX371279B (pt)
MY (1) MY180185A (pt)
NZ (1) NZ708321A (pt)
PH (1) PH12015500925A1 (pt)
SG (2) SG10201702828TA (pt)
TW (1) TWI643620B (pt)
UA (1) UA116549C2 (pt)
WO (1) WO2014065437A1 (pt)
ZA (1) ZA201503640B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1558582T3 (da) 2003-07-22 2006-05-08 Arena Pharm Inc Diaryl og arylheteroarylureaderivater som modulatorer af aktiviteten af 5-HT2A-serotoninreceptoren anvendelige til profylakse eller behandling af forstyrrelser relateret dertil
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
WO2009023253A2 (en) 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CN102264354B (zh) 2008-10-28 2015-03-25 艾尼纳制药公司 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
US20170042887A1 (en) * 2014-04-22 2017-02-16 Otsuka Pharmaceutical. Co., Ltd. Combination of Brexpiprazole and Nalmefene and Use Thereof for Treating Substance-Related Disorders
CN107249592A (zh) * 2015-01-12 2017-10-13 雷维瓦药品公司 用于治疗阿尔茨海默病的方法
WO2016115150A1 (en) * 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating psychosis associated with parkinson's disease
MX2017016413A (es) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
CN105175401A (zh) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 一种依匹哌唑的制备方法
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
RU2762896C2 (ru) 2016-12-20 2021-12-23 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин
RU2764443C2 (ru) 2016-12-20 2022-01-17 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
US10377708B2 (en) 2017-12-05 2019-08-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
EP3720434A4 (en) 2017-12-05 2021-09-01 Sunovion Pharmaceuticals Inc. NON-RACEMIC MIXTURES AND THEIR USE
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗***股份公司 含有阿塞那平的透皮治疗***
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
CN116113412A (zh) * 2020-06-24 2023-05-12 国立大学法人北海道大学 血液脑脊髓屏障保护剂
CN112137994B (zh) * 2020-09-15 2022-10-14 中山大学 小分子化合物在制备抗丝状病毒药物中的应用
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
AR085840A1 (es) * 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
EP2822136B1 (en) * 2013-07-03 2018-08-29 Siemens Aktiengesellschaft Method and arrangement for transferring electrical power for subsea applications

Also Published As

Publication number Publication date
TW201427665A (zh) 2014-07-16
CN114712360A (zh) 2022-07-08
CN108578408A (zh) 2018-09-28
HK1212609A1 (zh) 2016-06-17
JP2015535211A (ja) 2015-12-10
IL238402A0 (en) 2015-06-30
EP3848033A1 (en) 2021-07-14
JP2020045345A (ja) 2020-03-26
US20150272946A1 (en) 2015-10-01
NZ708321A (en) 2019-03-29
IL238402B (en) 2018-11-29
PH12015500925B1 (en) 2015-06-29
JP2021181448A (ja) 2021-11-25
MX2015005174A (es) 2015-09-04
PH12015500925A1 (en) 2015-06-29
EA201590808A1 (ru) 2015-08-31
US20190314367A1 (en) 2019-10-17
CN112402421A (zh) 2021-02-26
AR093247A1 (es) 2015-05-27
CA2889196C (en) 2021-02-16
SG10201702828TA (en) 2017-05-30
EP2911670A1 (en) 2015-09-02
ZA201503640B (en) 2016-08-31
JP6329140B2 (ja) 2018-05-23
WO2014065437A1 (en) 2014-05-01
JP2023123441A (ja) 2023-09-05
CN104755082A (zh) 2015-07-01
JP2018138555A (ja) 2018-09-06
UA116549C2 (uk) 2018-04-10
JOP20130313B1 (ar) 2021-08-17
SG11201503152TA (en) 2015-05-28
TWI643620B (zh) 2018-12-11
KR20150074156A (ko) 2015-07-01
MX371279B (es) 2020-01-24
AU2013335613A1 (en) 2015-06-04
KR102245016B1 (ko) 2021-04-26
JOP20210047A1 (ar) 2017-06-16
MY180185A (en) 2020-11-24
US20220370442A1 (en) 2022-11-24
AU2013335613B2 (en) 2018-07-12
CA2889196A1 (en) 2014-05-01
US20170258787A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
BR112015008759A2 (pt) método para a profilaxia e/ou tratamento de sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, agente profilático e/ou terapêutico para sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, uso de um composto, composto, e, composição farmacêutica
BR112014025711A2 (pt) composto, medicamento, e, uso de um composto
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112014007257A2 (pt) composto, medicamento, métodos para inibir um colesterol 24-hidrolase em um mamífero e para a profilaxia ou tratamento de doença neurodegenerativa em um mamífero, e, uso do composto ou sal
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112017005104A2 (pt) derivado de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112014017751A8 (pt) compostos inibidores de metaloenzima, métodos de inibir e modular a atividade de metaloenzina, composições contendo os ditos compostos e uso dos ditos compostos
BR112014022214A2 (pt) fenólicos antibacterianos
BR112012032087A2 (pt) composto, medicamento, e, uso de um composto
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
ES2425315R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
BR112015029353A2 (pt) derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112018002547A2 (pt) benzimidazóis substituídos, sua preparação e seu uso como produtos farmacêuticos
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112012026285A2 (pt) combinação de compostos orgânicos
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]